Nuclear Medicine Market Regional Analysis

Nuclear Medicine Market size was valued at USD 10.2 Billion in 2023 and is poised to grow from USD 11.53 Billion in 2024 to USD 25.12 Billion by 2032, growing at a CAGR of 13.00% during the forecast period (2025-2032).

The market is competitive with several market players adopting strategic collaborations in emerging economically favorable regions, contributing to the research and development. 'GE Healthcare ', 'Curium Pharma ', 'Novartis ', 'Cardinal Health ', 'Lantheus Medical Imaging ', 'Bracco Imaging S.P.A ', 'Jubilant Life Sciences Ltd ', 'Nordion (Canada), Inc. ', 'Siemens Healthineers ', 'Bayer AG ', 'Eckert & Ziegler ', 'Telix Pharmaceuticals ', 'NorthStar Medical Radioisotopes, LLC ', 'Shine Medical Technologies ', 'Isotopia Molecular Imaging Ltd. ', 'Institute of Isotopes Co., Ltd. ', 'Mediso Ltd. ', 'NTP Radioisotopes SOC Ltd. ', 'ITM Isotopen Technologien München AG ', 'Radiopharm Theranostics'

Most cases are preventable through early detection and treatment; nuclear medicine plays an important role in these areas. Cancer was the leading cause of death in 2020, accounting for nearly 10 million deaths, according to the WHO. By 2025, 19.3 million new cancer cases per year are expected to be reported worldwide. According to the WHO, 17.9 million people died from CVD in 2019, accounting for 32% of all deaths worldwide. By 2030, this figure is expected to rise to 23.3 million. Because nuclear medicine is used to diagnose and treat diseases, the rising prevalence of these diseases is expected to drive growth. 

Advancements in the Nuclear Medicine Therapies: Companies in the market are constantly focusing on the development of nuclear medicine therapies. The clinical effects of this treatment option in comparison to other therapies are driving its global demand. Furthermore, factors such as the sophistication of therapeutic application outcomes in the treatment of cancer and other disorders are expected to drive demand for nuclear medicine therapies in countries with a high cancer burden. For example, the US FDA granted Curium a Study May Proceed letter to begin its Phase-III trial with its investigational product, lutetium Lu 177 PSMA I&T. It is a radiopharmaceutical that binds to the protein Prostate-Specific Membrane Antigen (PSMA). Similarly, many market participants are developing new therapeutic products to treat a variety of medical conditions, which is driving market growth.

North America is the largest region in the nuclear medicine market and has a share of about 45.1% and is anticipated to grow add a considerable rate during the forecasted period. Due to the increased investment in R&D activities, high volume of nuclear medicine procedures, and strong health infrastructure is contributing towards the high market share of this region. For instance, Eckert and Ziegler made a development plan for cGMP facility in U.S. for contract manufacturing of radiopharmaceuticals. It will help in the production of late investigational stage and commercial stage radioisotopes which are used in nuclear medicine and help in contributing to the increasing demand for radionuclides in the market.